O M Koper1, J Kamińska2, K Sawicki3, J Reszeć4, R Rutkowski3, M Jadeszko3, Z Mariak3, V Dymicka-Piekarska2, H Kemona2. 1. Department of Clinical Laboratory Diagnostics, Medical University of Bialystok, ul. Waszyngtona 15A, 15-269, Białystok, Poland. o.koper@wp.pl. 2. Department of Clinical Laboratory Diagnostics, Medical University of Bialystok, ul. Waszyngtona 15A, 15-269, Białystok, Poland. 3. Department of Neurosurgery, Clinical Hospital of the Medical University of Bialystok, Białystok, Poland. 4. Department of Pathomorphology, Medical University of Bialystok, Białystok, Poland.
Abstract
BACKGROUND: The aim of the study was the evaluation of serum and CSF concentrations of CCL2, IL-8, and sICAM-1 in patients with astrocytic tumors as compared to a group of non-tumoral patients. METHODS: Chemokine concentrations were measured using the ELISA method. RESULTS: Regardless of the parameter tested and the patient group (brain tumor or non-tumoral patients), statistical differences (P < 0.05) were found between concentrations obtained in CSF compared to values obtained in serum for all proteins tested. CSF IL-8 concentrations were significantly elevated in CNS tumor patients as compared to non-tumoral individuals (P = 0.000); serum CCL2 and sICAM-1 concentrations were significantly decreased in CNS tumors in comparison with the comparative group (P = 0.002 and P = 0.026, respectively). Among proteins tested in the serum, a higher area under the ROC curve (AUC) revealed CCL2 compared to sICAM-1 in differentiating subjects with CNS brain tumors from non-tumoral subjects. AUC for CSF IL-8 was higher than for its index (CSF IL-8/serum IL-8). CONCLUSIONS: For individual biomarkers (IL-8 and CCL2, sICAM-1), measured in CNS brain tumor patients, the appropriate material, respectively CSF or serum, should be chosen and quantitatively tested. Increased cerebrospinal fluid IL-8 with decreased serum CCL2 create a pattern of biomarkers, which may be helpful in the management of CNS astrocytic brain tumors.
BACKGROUND: The aim of the study was the evaluation of serum and CSF concentrations of CCL2, IL-8, and sICAM-1 in patients with astrocytic tumors as compared to a group of non-tumoralpatients. METHODS: Chemokine concentrations were measured using the ELISA method. RESULTS: Regardless of the parameter tested and the patient group (brain tumor or non-tumoralpatients), statistical differences (P < 0.05) were found between concentrations obtained in CSF compared to values obtained in serum for all proteins tested. CSF IL-8 concentrations were significantly elevated in CNS tumorpatients as compared to non-tumoral individuals (P = 0.000); serum CCL2 and sICAM-1 concentrations were significantly decreased in CNS tumors in comparison with the comparative group (P = 0.002 and P = 0.026, respectively). Among proteins tested in the serum, a higher area under the ROC curve (AUC) revealed CCL2 compared to sICAM-1 in differentiating subjects with CNS brain tumors from non-tumoral subjects. AUC for CSF IL-8 was higher than for its index (CSF IL-8/serum IL-8). CONCLUSIONS: For individual biomarkers (IL-8 and CCL2, sICAM-1), measured in CNS brain tumorpatients, the appropriate material, respectively CSF or serum, should be chosen and quantitatively tested. Increased cerebrospinal fluid IL-8 with decreased serum CCL2 create a pattern of biomarkers, which may be helpful in the management of CNS astrocytic brain tumors.
Authors: Dieta Brandsma; Emile E Voest; Wilco de Jager; Hans Bonfrer; Ale Algra; Willem Boogerd; Tiny Korse; Jaap C Reijneveld; Marcel M Verbeek; Ger Rijkers; Martin J B Taphoorn Journal: J Neurol Date: 2006-09-22 Impact factor: 4.849
Authors: U M Domanska; R C Kruizinga; W F A den Dunnen; H Timmer-Bosscha; E G E de Vries; A M E Walenkamp Journal: Crit Rev Oncol Hematol Date: 2010-08-14 Impact factor: 6.312
Authors: Emilia Lubowicka; Andrzej Przylipiak; Monika Zajkowska; Barbara Maria Piskór; Paweł Malinowski; Wojciech Fiedorowicz; Sławomir Ławicki Journal: Biomed Res Int Date: 2018-07-30 Impact factor: 3.411
Authors: Olga M Koper-Lenkiewicz; Anna J Milewska; Joanna Kamińska; Karol Sawicki; Robert Chrzanowski; Justyna Zińczuk; Joanna Reszeć; Marzena Tylicka; Ewa Matuszczak; Joanna Matowicka-Karna; Zenon Mariak; Mariusz W Mucha; Robert Pawlak; Violetta Dymicka-Piekarska Journal: Ann Med Date: 2021-12 Impact factor: 4.709